Clinical trial
Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic…
NCT00079755 · Seagen Inc., Industry · Completed
Key facts
| NCT number | NCT00079755 |
|---|---|
| Title | Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma |
| Official title | A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Refractory or Recurrent Hodgkin's Disease or Anaplastic Large Cell Lymphoma |
| Lead sponsor | Seagen Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anaplastic Large-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | SGN-30 (anti-CD30 mAb) |
| Enrollment | 80 |
| Start date | Feb 1, 2004 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Mar 16, 2004 |
| Last update posted | Dec 18, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: